Gene mutation and targeted therapy development of gastrointestinal stromal tumors
- VernacularTitle:胃肠间质瘤基因突变和分子靶向治疗相关研究进展
- Author:
Wenchao CHEN
;
Xiefu ZHANG
;
Chunlin ZHAO
;
Tao LIU
- Publication Type:Journal Article
- Keywords:
gastrointestinal stromal tumors;
imatinib mesylate;
KIT;
PDGFRA
- From:
International Journal of Surgery
2008;35(5):333-335
- CountryChina
- Language:Chinese
-
Abstract:
Gastrointestinal stromal tumors are the common mesenchymal tumors of the gastrointestinal tract. The constitutive activation of KIT is one of the earlies ttransforming events in GISTs and occurs mainly through activating mutations in the kit gene. PDGFRa is associated with the pathogenesis of GISTs too. The main mutative site of KIT gene are exon11, exon9, exon13 and exon17 and those of PDGFRA are exon18, exon12 and exon14.The clinical parameter and the response to imatinib of GISTs are associated with the site and type of gene mutation. Imatinib mesylate is a small-molecule inhibitor that selectively inhibit the tyrosine kinase and the clinical use of it is one milestone of the targeted therapy of GISTs. We review the gene mutation and targeted therapy development of gastrointestinal stromal tumors in this article.
